Laboratorios Richmond SACIF
BCBA:RICH
Laboratorios Richmond SACIF
Note Receivable
Laboratorios Richmond SACIF
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Laboratorios Richmond SACIF
BCBA:RICH
|
Note Receivable
1.2B
|
CAGR 3-Years
528%
|
CAGR 5-Years
217%
|
CAGR 10-Years
N/A
|
|
Laboratorios Richmond SACIF
Glance View
Laboratorios Richmond SACIF manufactures pharmaceutical products. The company is headquartered in Buenos Aires, Buenos Aires. The company went IPO on 2017-12-22. The firm's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
See Also
What is Laboratorios Richmond SACIF's Note Receivable?
Note Receivable
1.2B
ARS
Based on the financial report for Sep 30, 2025, Laboratorios Richmond SACIF's Note Receivable amounts to 1.2B ARS.
What is Laboratorios Richmond SACIF's Note Receivable growth rate?
Note Receivable CAGR 5Y
217%
Over the last year, the Note Receivable growth was -4%. The average annual Note Receivable growth rates for Laboratorios Richmond SACIF have been 528% over the past three years , 217% over the past five years .
